JY
KBIO

Jeff Yass’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

Jeff Yass’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-7,984
Closed -$31K – 10916
2015
Q1 		$31K Buy
+7,984
New +$35.8K ﹤0.01% 9228

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Jeff Yass's KBIO Position: Q2 2015 in Review

Jeff Yass sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q2 2015, closing a stake of 7,984 shares — an estimated $31K sold.

Jeff Yass first reported a position in KBIO in Q1 2015 and held it in 1 quarter. The position peaked at $31K in Q1 2015. 19 funds tracked by Wall St. Rank hold KBIO as of Q2 2015.

  • Jeff Yass reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q2 2015 after selling out during the quarter.
  • Jeff Yass sold 7,984 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q2 2015, an estimated $31K.
  • Jeff Yass first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q1 2015 and held it in 1 quarter.
  • Jeff Yass's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $31K in Q1 2015.
  • 19 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q2 2015.

Based on Susquehanna International Group's 13F filing for Q2 2015, filed 14 Aug 2015.